AVF3963s Neoadjuvant Bevacizumab and Carboplatin Followed by Concurrent Bevacizumab, Carboplatin and Radiotherapy in the Primary Treatment of Cervix Cancer.

Trial Profile

AVF3963s Neoadjuvant Bevacizumab and Carboplatin Followed by Concurrent Bevacizumab, Carboplatin and Radiotherapy in the Primary Treatment of Cervix Cancer.

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 25 Nov 2014

At a glance

  • Drugs Bevacizumab (Primary) ; Carboplatin (Primary)
  • Indications Adenocarcinoma; Cervical cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 27 Apr 2011 Planned end date changed from 1 Jan 2010 to 1 Apr 2011 as reported by ClinicalTrials.gov.
    • 27 Apr 2011 Status changed from active, no longer recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 05 Oct 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top